Signal
FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-30 18:52 UTCUpdated 2026-05-01 15:58 UTC
rss
fierce_pharma
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults.
Score total
1.05
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Four years after gaining FDA approval for Auvelity to treat major depressive disorder, Axsome Therapeutics has tacked on a second nod in the united States for the first-in-class...
Fierce Pharma (All) · fiercepharma.com · 2026-05-01 15:58 UTC
FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia
fda_press_releases · fda.gov · 2026-04-30 18:52 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- fda_press_releases (1)
Top origin domains (this list)
- fiercepharma.com (1)
- fda.gov (1)